Characterization and functional analysis of scFv-based chimeric antigen receptors to redirect T Cells to IL13Rα2-positive glioma

Molecular Therapy

Volumn 24, Issue 2, 2016, Pages 354-363

  Krenciute, Giedre ^a,b   Krebs, Simone ^a,b   Torres, David ^a,b   Wu, Meng Fen ^b   Liu, Hao ^b   Dotti, Gianpietro ^c   Li, Xiao Nan ^b   Lesniak, Maciej S ^d   Balyasnikova, Irina V ^d   Gottschalk, Stephen ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 13 RECEPTOR ALPHA2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COCULTURE; CONTROLLED STUDY; CROSS REACTION; EMBRYO; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PROTEIN DOMAIN; T LYMPHOCYTE; ANIMAL; BRAIN NEOPLASMS; DRUG SCREENING; IMMUNOLOGY; METABOLISM; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; GLIOBLASTOMA; HUMANS; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MICE; SINGLE-CHAIN ANTIBODIES; SURVIVAL ANALYSIS; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84959525977     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.199     Document Type: Article

References (50)

1. Suryadevara, CM, Verla, T, Sanchez-Perez, L, Reap, EA, Choi, BD, Fecci, PE, et al. (2015). Immunotherapy for malignant glioma. Surg Neurol Int 6(Suppl 1): S68-S77.
2. Van Gool, SW (2015). Brain Tumor Immunotherapy: What have We Learned so Far? Front Oncol 5: 98.
3. Reardon, DA, Freeman, G, Wu, C, Chiocca, EA, Wucherpfennig, KW, Wen, PY, et al. (2014). Immunotherapy advances for glioblastoma. Neuro Oncol 16: 1441-1458.
4. Ahmed, N, Salsman, VS, Kew, Y, Shaffer, D, Powell, S, Zhang, YJ, et al. (2010). HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 16: 474-485.
5. Chow, KK, Naik, S, Kakarla, S, Brawley, VS, Shaffer, DR, Yi, Z, et al. (2013). T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther 21: 629-637.
6. Johnson, LA, Scholler, J, Ohkuri, T, Kosaka, A, Patel, PR, McGettigan, SE, et al. (2015). Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med 7: 275ra22.
7. Krebs, S, Chow, KK, Yi, Z, Rodriguez-Cruz, T, Hegde, M, Gerken, C, et al. (2014). T cells redirected to interleukin-13Rα2 with interleukin-13 mutein-chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1. Cytotherapy 16: 1121-1131.
8. Kong, S, Sengupta, S, Tyler, B, Bais, AJ, Ma, Q, Doucette, S, et al. (2012). Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res 18: 5949-5960.
9. Brown, CE, Starr, R, Aguilar, B, Shami, AF, Martinez, C, D'Apuzzo, M, et al. (2012). Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res 18: 2199-2209.
10. Brown, CE, Badie, B, Barish, ME, Weng, L, Ostberg, JR, Chang, WC, et al. (2015). Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. Clin Cancer Res 21: 4062-4072.
11. Sampson, JH, Choi, BD, Sanchez-Perez, L, Suryadevara, CM, Snyder, DJ, Flores, CT, et al. (2014). EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-Antigen loss. Clin Cancer Res 20: 972-984.
12. Okada, H, Low, KL, Kohanbash, G, McDonald, HA, Hamilton, RL and Pollack, IF (2008). Expression of glioma-Associated antigens in pediatric brain stem and non-brain stem gliomas. J Neurooncol 88: 245-250.
13. Joshi, BH, Puri, RA, Leland, P, Varricchio, F, Gupta, G, Kocak, M, et al.; US Pediatric Brain Tumor Consortium. (2008). Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma. Neuro Oncol 10: 265-274.
14. Kawakami, M, Kawakami, K, Takahashi, S, Abe, M and Puri, RK (2004). Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors. Cancer 101: 1036-1042.
15. Brown, CE, Warden, CD, Starr, R, Deng, X, Badie, B, Yuan, YC, et al. (2013). Glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis. PLoS One 8: e77769.
16. Hsi, LC, Kundu, S, Palomo, J, Xu, B, Ficco, R, Vogelbaum, MA, et al. (2011). Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signaling. Mol Cancer Ther 10: 1149-1160.
17. Fichtner-Feigl, S, Strober, W, Kawakami, K, Puri, RK and Kitani, A (2006). IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 12: 99-106.
18. Bartolomé, RA, García-Palmero, I, Torres, S, López-Lucendo, M, Balyasnikova, IV and Casal, JI (2015). IL13 Receptor α2 Signaling Requires a Scaffold Protein, FAM120A, to Activate the FAK and PI3K Pathways in Colon Cancer Metastasis. Cancer Res 75: 2434-2444.
19. Dotti, G, Gottschalk, S, Savoldo, B and Brenner, MK (2014). Design and development of therapies using chimeric antigen receptor-Expressing T cells. Immunol Rev 257: 107-126.
20. Jensen, MC and Riddell, SR (2015). Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol 33: 9-15.
21. Sadelain, M, Brentjens, R and Rivière, I (2013). The basic principles of chimeric antigen receptor design. Cancer Discov 3: 388-398.
22. Kahlon, KS, Brown, C, Cooper, LJ, Raubitschek, A, Forman, SJ and Jensen, MC (2004). Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 64: 9160-9166.
23. Balyasnikova, IV, Wainwright, DA, Solomaha, E, Lee, G, Han, Y, Thaci, B, et al. (2012). Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2. J Biol Chem 287: 30215-30227.
24. Kim, J, Young, J, Solomaha, E, Kanojia, D, Lesniak, MS, Balyasnikova, IV (2015). A novel single-chain antibody redirects adenovirus to IL13Ra2-Expressing brain tumors. Sci Rep (accepted for publication)
25. Beard, RE, Abate-Daga, D, Rosati, SF, Zheng, Z, Wunderlich, JR, Rosenberg, SA, et al. (2013). Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy. Clin Cancer Res 19: 4941-4950.
26. Fujisawa, T, Nakashima, H, Nakajima, A, Joshi, BH and Puri, RK (2011). Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine. Int J Cancer 128: 1221-1231.
27. Barderas, R, Bartolomé, RA, Fernandez-Aceñero, MJ, Torres, S and Casal, JI (2012). High expression of IL-13 receptor α2 in colorectal cancer is associated with invasion, liver metastasis and poor prognosis. Cancer Res 72: 2780-2790.
28. Kunwar, S, Prados, MD, Chang, SM, Berger, MS, Lang, FF, Piepmeier, JM, et al.; Cintredekin Besudotox Intraparenchymal Study Group. (2007). Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 25: 837-844.
29. Okada, H, Kalinski, P, Ueda, R, Hoji, A, Kohanbash, G, Donegan, TE, et al. (2011). Induction of CD8+ T-cell responses against novel glioma-Associated antigen peptides and clinical activity by vaccinations with {alpha}-Type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29: 330-336.
30. Kioi, M, Seetharam, S and Puri, RK (2008). Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol Cancer Ther 7: 1579-1587.
31. Hudecek, M, Lupo-Stanghellini, MT, Kosasih, PL, Sommermeyer, D, Jensen, MC, Rader, C, et al. (2013). Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 19: 3153-3164.
32. Haso, W, Lee, DW, Shah, NN, Stetler-Stevenson, M, Yuan, CM, Pastan, IH, et al. (2013). Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121: 1165-1174.
33. Chow, KH and Gottschalk, S (2011). Cellular immunotherapy for high-grade glioma. Immunotherapy 3: 423-434.
34. Schuessler, A, Smith, C, Beagley, L, Boyle, GM, Rehan, S, Matthews, K, et al. (2014). Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res 74: 3466-3476.
35. Künkele, A, Johnson, AJ, Rolczynski, LS, Chang, CA, Hoglund, V, Kelly-Spratt, KS, et al. (2015). Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD. Cancer Immunol Res 3: 368-379.
36. Hoyos, V, Savoldo, B, Quintarelli, C, Mahendravada, A, Zhang, M, Vera, J, et al. (2010). Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24: 1160-1170.
37. Pegram, HJ, Lee, JC, Hayman, EG, Imperato, GH, Tedder, TF, Sadelain, M, et al. (2012). Tumor-Targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119: 4133-4141.
38. Avril, T, Saikali, S, Vauleon, E, Jary, A, Hamlat, A, De Tayrac, M, et al. (2010). Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-Dioxygenase (IDO) on tumour-specific T cell functions. J Neuroimmunol 225: 22-33.
39. Parsa, AT, Waldron, JS, Panner, A, Crane, CA, Parney, IF, Barry, JJ, et al. (2007). Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13: 84-88.
40. Gottschalk, S, Ng, CY, Perez, M, Smith, CA, Sample, C, Brenner, MK, et al. (2001). An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97: 835-843.
41. Sampson, JH, Heimberger, AB, Archer, GE, Aldape, KD, Friedman, AH, Friedman, HS, et al. (2010). Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28: 4722-4729.
42. Grada, Z, Hegde, M, Byrd, T, Shaffer, DR, Ghazi, A, Brawley, VS, et al. (2013). TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Mol Ther Nucleic Acids 2: e105.
43. Hegde, M, Corder, A, Chow, KK, Mukherjee, M, Ashoori, A, Kew, Y, et al. (2013). Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 21: 2087-2101.
44. Anurathapan, U, Chan, RC, Hindi, HF, Mucharla, R, Bajgain, P, Hayes, BC, et al. (2014). Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther 22: 623-633.
45. Kochenderfer, JN, Yu, Z, Frasheri, D, Restifo, NP and Rosenberg, SA (2010). Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116: 3875-3886.
46. Liu, Z, Zhao, X, Mao, H, Baxter, PA, Huang, Y, Yu, L, et al. (2013). Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma. Neuro Oncol 15: 1173-1185.
47. Sarkaria, JN, Yang, L, Grogan, PT, Kitange, GJ, Carlson, BL, Schroeder, MA, et al. (2007). Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 6: 1167-1174.
48. Pulè, MA, Straathof, KC, Dotti, G, Heslop, HE, Rooney, CM and Brenner, MK (2005). A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 12: 933-941.
49. Vera, J, Savoldo, B, Vigouroux, S, Biagi, E, Pule, M, Rossig, C, et al. (2006). T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-Derived malignant cells. Blood 108: 3890-3897.
50. Xu, Y, Zhang, M, Ramos, CA, Durett, A, Liu, E, Dakhova, O, et al. (2014). Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123: 3750-3759.